British giant Glaxo has made millions of doses of ANOTHER vaccine

British drugs giant Glaxo has already made millions of doses of ANOTHER vaccine – raising hopes of it being made available early next year

  • British drugs giant GlaxoSmithKline has raised hopes of another Covid vaccine
  • American giant Pfizer last week revealed its Covid vaccine is 90% effective
  • GSK is working in three international tie-ups to develop an effective injection

British drugs giant GlaxoSmithKline has raised hopes of another Covid vaccine being made available early next year after revealing that it has already manufactured ‘millions of doses’.

Roger Connor, its president of global vaccines, told The Mail on Sunday that GlaxoSmithKline (GSK) had launched mass production and was now set to move into the final stage of trials.

‘We’re already getting into the millions of doses manufactured,’ he added. ‘We’re fully resourced and moving – in fact, we were celebrating starting up our Belgium facility the week before last.

British drugs giant GlaxoSmithKline has raised hopes of another Covid vaccine being made available early next year after revealing that it has already manufactured ‘millions of doses’. Pictured: Headquarters in west London 

‘You can imagine the sense of pride that creates in people working on it. They are completely buzzing because they know they’re going to make a difference.’

It comes after American giant Pfizer last week revealed its Covid vaccine is 90 per cent effective and could be available before Christmas.

GSK has committed to producing a billion doses of its jab next year and has previously said it was aiming for safety approval in the ‘first half of 2021’.

However, news of the ramp-up in manufacturing and progression of the trials will raise hopes the company can gain approval even earlier, opening up the possibility that its vaccine could be available by the spring.

GSK has committed to producing a billion doses of its jab next year (stock image) and has previously said it was aiming for safety approval in the ‘first half of 2021′

The MoS understands announcements from the other drug firms racing to produce a Covid-19 vaccine are also imminent.

The results of trials by UK giant AstraZeneca and Oxford University – which are working together on a vaccine – could come as early as this week or next week. Meanwhile, America’s Johnson & Johnson and Moderna are also thought to be nearing announcements.

GSK is working in three international tie-ups to develop an effective injection, all of which are set to move to the final stages of testing.

GSK is producing a so-called adjuvant – an ingredient used to create a strong immune response – which will be combined with antigens produced by French drugs firm Sanofi, Canada’s Medicago and China’s Clover Biopharmaceuticals, to create a vaccine. The vaccine is being made at sites across the UK, Europe, Canada and the US.

The GSK-Medicago trial of a plant-based vaccine is moving towards its final stages, with 30,000 volunteers across North America, Latin America and potentially Europe included in the tests.

The vaccine being produced by US pharma giant Pfizer (pictured, facility in Puurs, Belgium) and Germany’s BioNTech is based on newer technology than GSK is using

Mr Connor said trials for the GSK-Clover link-up will begin ‘in a couple of weeks’ and the GSK-Sanofi partnership could move into mass human testing ‘in the next few weeks’ after receiving encouraging results. He added: ‘We’re looking for approval of our vaccines in that first half of 2021 – the world’s going to need them.’

The vaccine being produced by US pharma giant Pfizer and Germany’s BioNTech is based on newer technology than GSK is using.

As a result, Pfizer’s vaccine will need to be stored below minus 70C. The vaccines being developed by GSK, AstraZeneca and Johnson & Johnson can all be stored at normal fridge temperature.

But news of the potential breakthrough comes as a leading expert warned that a limited supply of the raw ingredients needed for Covid vaccines such as Pfizer’s risks leaving much of the world’s population unprotected. 

Andrey Zarur, chief executive of GreenLight Biosciences, said that because the jabs are based on new technology, suppliers of the materials needed to make them do not yet have the capacity to churn out the vast quantities required.

‘The supply chain is just not mature enough. They have existed for laboratory-scale processes, which need nanograms, but they have to go from nanogram scale, to kilogram scale,’ he added.

Source: Read Full Article